Cart
sales@molnova.com
Prazosin
CAS No. 19216-56-9
Prazosin( Furazosin | Prazosine | Prazocin )
Catalog No. M23872 CAS No. 19216-56-9
Prazosin, an α1-blocker, acts as an inverse agonist at alpha-1 adrenergic receptors and is used to treat hypertension.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 38 | In Stock |
|
| 25MG | 59 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePrazosin
-
NoteResearch use only, not for human use.
-
Brief DescriptionPrazosin, an α1-blocker, acts as an inverse agonist at alpha-1 adrenergic receptors and is used to treat hypertension.
-
DescriptionPrazosin, an α1-blocker, acts as an inverse agonist at alpha-1 adrenergic receptors and is used to treat hypertension.
-
In Vitro——
-
In Vivo——
-
SynonymsFurazosin | Prazosine | Prazocin
-
PathwayApoptosis
-
TargetAdenosine Receptor
-
Recptorα1-adrenergic receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number19216-56-9
-
Formula Weight383.4
-
Molecular FormulaC19H21N5O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 41.67 mg/mL (108.69 mM)
-
SMILESCOc(cc1c(N)nc(N(CC2)CCN2C(c2ccco2)=O)nc1c1)c1OC
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Mindi Zhao, et al. PLoS One. 2016, 11(10): e0164796.
molnova catalog
related products
-
Binodenoson
Binodenoson is a potent and selective A2A adenosine receptor agonist (KD=270 nM). Binodenoson is being developed as a short-acting coronary vasodilator as an adjunct to radiotracers for use in myocardial stress imaging.
-
DPCPX
DPCPX is an A1 adenosine receptor antagonist
-
Xanthine amine conge...
Xanthine amine congener trihydrochloride is a potent adenosine antagonist that reverses the reduction in urine flow, sodium excretion and heart rate produced by the adenosine agonist, N6-cyclohexyladenosine.
